What Is Anti-Obesity Medication & How Does It Work?

Anti-obesity medications are prescription drugs designed to reduce body weight by changing how the body regulates appetite, absorbs nutrients, or burns energy. The newest and most effective class, injectable incretin-based drugs like semaglutide and tirzepatide, produce average weight loss in the range of 15–20% of body weight over roughly 12 to 18 months.¹ But the category is broader than one drug class, and the mechanisms behind these medications are more interesting than the simple phrase “appetite suppressant” suggests.

How the Field Got Here

Doctors have been prescribing drugs for weight loss since the 1930s, and most of that history is a cautionary tale. One of the earliest agents, a chemical called dinitrophenol (DNP), caused weight loss by speeding up metabolism at a cellular level. It also caused cataracts and occasionally killed people. Amphetamines dominated obesity treatment through the 1940s and 1950s, bringing predictable problems with dependence and heart damage. Several drugs approved in the 1990s were eventually yanked from the market over safety concerns, most famously the “fen-phen” combination that caused heart valve disease.²

What changed the game was a deeper scientific understanding of the hormones that control hunger. Researchers discovered that the gut releases signaling molecules after eating, and these molecules talk directly to the brain to regulate how much food you want. The first drug to exploit this biology at scale was liraglutide, a modified version of a natural gut hormone called GLP-1. Its success opened the door to semaglutide, tirzepatide, and an entire pipeline of newer drugs that work on the same hormonal pathways but with increasing potency.¹

How GLP-1 Drugs Work in the Brain

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally produces after meals. In its natural form, it breaks down in about a minute and a half. Drugs like semaglutide and liraglutide are engineered versions that last much longer in the bloodstream, which means they can activate GLP-1 receptors continuously rather than in brief post-meal bursts.²

The key action happens in the brain. GLP-1 receptors sit on neurons in the hypothalamus, the brain region that governs hunger and fullness, and also in areas of the parietal cortex and medulla. Imaging studies in people with diabetes found that giving a GLP-1 drug (liraglutide) decreased activation in the insula and putamen, areas tied to the brain’s reward system.³ In a separate trial, another GLP-1 drug (exenatide) reduced food intake and blunted brain responses to food in the insula, amygdala, putamen, and orbitofrontal cortex, and these effects were largely blocked when researchers pre-treated participants with a GLP-1 receptor blocker.⁴

Put plainly, these drugs do not just make you feel less hungry. They seem to reduce how rewarding food feels, particularly highly desirable or calorie-dense food. People on GLP-1 medications frequently describe losing interest in foods they previously craved, and the brain imaging data suggest a biological basis for that experience.

GLP-1 is not the only gut hormone involved in appetite regulation. Another hormone called GIP (glucose-dependent insulinotropic polypeptide) also acts on brain regions involved in appetite and satiety. Both GIP and GLP-1 appear to influence food intake through pathways in the hypothalamus, including by modulating appetite-stimulating signals.⁵ This dual hormone story is what led to the development of drugs that activate both receptors at once.

Dual and Triple Agonists

Tirzepatide, sold as Mounjaro and Zepbound, was the first drug to activate both the GLP-1 and GIP receptors simultaneously. The logic was that hitting two appetite-related pathways at once would produce more weight loss than hitting one alone, and that turned out to be correct. Preclinical research showed that the combined effect on body weight requires specific neurons in the central nervous system that express GIP receptors and use the neurotransmitter GABA, suggesting the two hormone signals cooperate inside the brain rather than simply adding together.⁶

The field has already moved beyond dual agonists. Retatrutide is a triple agonist, activating the GLP-1, GIP, and glucagon receptors. The glucagon component adds something the other two do not: it stimulates the liver to burn more fat and produce less new fat, while also increasing overall energy expenditure. In a phase 2 obesity study, the higher doses of retatrutide produced weight reductions of roughly 23–24% over 48 weeks.⁷ Retatrutide also showed dramatic reductions in liver fat in people with fatty liver disease, with higher doses reducing liver fat by more than 80% compared to baseline after 24 weeks.⁷

Older and Alternative Drug Classes

Not every anti-obesity medication works through gut hormones. Several other approaches remain on the market, each with a distinct mechanism.

Orlistat works entirely in the digestive tract rather than the brain. It binds to lipase enzymes in the stomach and small intestine, blocking them from breaking down dietary fat. The undigested fat passes through and is excreted.⁸ In practice, the degree of fat blocking depends on the type of meal. With solid meals, orlistat inhibits gastric lipase rapidly and can lead to 40–57% of ingested fat being excreted unabsorbed. With liquid meals containing pre-emulsified fats, the effect is much smaller because the fat gets digested before orlistat can shut down the enzymes.⁹ The practical consequence is oily stools and digestive discomfort, especially with high-fat meals, which acts as a kind of behavioral deterrent on top of the pharmacological effect.

Naltrexone/bupropion (sold as Contrave) works through an entirely different brain pathway. Bupropion stimulates neurons in the hypothalamus that produce a satiety signal, but these neurons normally self-regulate by releasing natural opioids that dampen their own activity. Naltrexone blocks that opioid-driven “off switch,” keeping the satiety signal running longer.¹⁰ The combination also appears to reduce the brain’s reactivity to food cues, though the full picture of how it works is still being pieced together.

Phentermine/topiramate (Qsymia) combines a mild stimulant with an anti-seizure drug that happens to suppress appetite. This combination has been around for over a decade and produces meaningful weight loss, though less than the newer incretin drugs.

How the Drugs Compare on Weight Loss

A large 2026 network meta-analysis in the BMJ ranked available drugs by how much weight they produced beyond lifestyle changes alone. The results showed a clear hierarchy. Tirzepatide and CagriSema (a combination of semaglutide and cagrilintide) topped the list, each producing roughly 15% additional weight reduction with moderate-to-high certainty. Oral and injectable semaglutide, orforglipron, and phentermine-topiramate fell in the middle tier, producing around 8–11% additional weight loss. Liraglutide, naltrexone-bupropion, and orlistat were not convincingly more effective than lifestyle modification alone in the network analysis.¹¹

That last finding may surprise people who have been prescribed those older drugs. In real-world clinical practice, the numbers look somewhat different. A study of over 200 patients on various anti-obesity drugs found that about 87% of phentermine users and 75% of lorcaserin users hit at least 5% weight loss within six months, compared to about 58% for liraglutide and 35% for naltrexone/bupropion.¹² The discrepancy between trial-level meta-analyses and real-world data is partly about populations, partly about adherence, and partly about what counts as the comparison group. The takeaway for patients is that even drugs with modest average results in meta-analyses can work well for some individuals, but the ceiling for weight loss is substantially higher with the newer incretin-based drugs.

What Happens When You Stop

One of the most important things to understand about anti-obesity medication is that it generally needs to be continued. The STEP 1 trial extension tracked people who stopped taking semaglutide after 68 weeks and found that participants regained an average of 11.6 percentage points of body weight over the following year. By the end of the off-treatment period, the net weight loss from baseline was only about 5.6%, down from the roughly 15% achieved during active treatment.¹³

This is not unique to semaglutide. Evidence from major trial programs suggests that up to two-thirds of lost body weight may come back within a year of stopping therapy. The mechanisms driving regain include a drop in resting metabolic rate that overshoots what you would predict from the new lower weight, loss of lean tissue, and a resurgence of appetite hormones that had been suppressed by the drug.¹⁴ This pattern reinforces something obesity researchers have been saying for years: obesity is a chronic condition that tends to reassert itself when treatment stops, much like blood pressure climbing back up when you discontinue a blood pressure pill.

The Muscle Question

Rapid weight loss from any cause, whether surgery, extreme dieting, or medication, inevitably costs some muscle. GLP-1 drugs are no exception, and the concern has been that the large amount of weight lost might come disproportionately from lean tissue. Recent evidence is more reassuring than early fears suggested. A study combining preclinical work in mice with a proof-of-concept clinical trial found that GLP-1 drugs predominantly reduce body fat, with lean body mass contributing roughly 20% of total weight lost. While absolute muscle mass decreased slightly, relative muscle mass and strength improved because fat loss so dramatically outpaced muscle loss. In the mouse studies, the animals actually showed better running performance on the drugs.¹⁵

Among lean tissues, liver mass decreased more than skeletal muscle, which makes physiological sense: the liver accumulates fat during obesity and sheds it during weight loss. The overall picture from that work was that patients with obesity who took GLP-1 drugs improved their body composition without a meaningful hit to strength.¹⁵

That said, the concern is more legitimate for certain groups. Older adults, people who already have low muscle mass relative to their fat (sometimes called sarcopenic obesity), and those with type 2 diabetes are at higher risk of clinically meaningful lean tissue loss.¹⁶ For these populations, experts increasingly recommend pairing anti-obesity medication with resistance training and adequate protein intake to protect muscle during rapid weight loss.

Cardiovascular Effects Beyond Weight

GLP-1 drugs appear to have heart benefits that go beyond what you would expect from the weight loss itself. An analysis of GLP-1 receptor agonists in patients with a form of heart failure called HFpEF found that the drugs reduced hospitalizations for heart failure compared to an active comparator (insulin glargine), and this protective effect was not explained by weight loss. The researchers noted that GLP-1 drugs and another drug class (SGLT2 inhibitors) showed equivalent risk reduction, suggesting direct cardiac and vascular effects that still need further exploration.¹⁷

This matters because it reframes the drug’s value proposition. If GLP-1 medications only helped because they caused weight loss, you could argue that any method of losing weight would produce the same cardiovascular benefit. The emerging evidence that the drugs have direct effects on the heart and blood vessels suggests they may be doing something qualitatively different from a diet that produces the same number of pounds lost.

Use in Children and Adolescents

GLP-1 drugs are being studied and, in some cases, prescribed to adolescents with severe obesity. A meta-analysis of randomized controlled trials found that GLP-1 receptor agonists significantly reduced body weight, BMI, blood sugar markers, and systolic blood pressure in children and adolescents compared to placebo. The overall rate of adverse events was similar between drug and placebo groups, though gastrointestinal side effects like nausea were more common with the drugs. There was no significant increase in suicidal ideation or behaviors.¹⁸

Among the specific drugs studied, subcutaneous semaglutide at the adult dose showed the largest effects in a network meta-analysis: an average weight reduction of 18 kg, a BMI drop of about 5.9 points, and a waist circumference decrease of roughly 12 cm.¹⁹ These are large effects for a teenage patient. The question of long-term safety over years of use during growth and development remains open, but the short- and medium-term data are encouraging enough that prescribing has expanded.

Access and Affordability

Despite how well the newer drugs work, getting them remains a major challenge for many people. Access to anti-obesity medications is hampered by high manufacturer prices, inconsistent insurance coverage, supply shortages, and a lack of provider familiarity with how to navigate coverage barriers.²⁰ Many insurers, including Medicare until recently, excluded anti-obesity drugs from coverage entirely, treating them as elective rather than medically necessary. This has left patients in a frustrating bind: evidence-based treatments exist, but large portions of the population cannot afford them out of pocket.²¹

The situation is evolving. Legislative changes, generic competition, and the development of oral versions of incretin drugs are all gradually shifting the landscape. But for now, cost remains the single biggest practical barrier between many patients and the most effective treatments available.

The Oral Pill Frontier

Most GLP-1 drugs are injected once a week, which is a barrier for some patients. Oral semaglutide was the first pill-form GLP-1 drug to reach the market, and how it works is an interesting engineering problem. GLP-1 is a peptide, and peptides get destroyed by stomach acid and digestive enzymes within minutes. To get around this, oral semaglutide is co-formulated with a compound called SNAC that protects the drug in the stomach and helps it cross the stomach lining into the bloodstream intact.²² The SNAC molecule raises the local pH around the tablet, shielding semaglutide from enzymatic breakdown and enhancing absorption through the gastric membrane.²³

The catch is that oral bioavailability is still relatively low compared to injection, which means higher doses are needed by mouth to achieve comparable blood levels. In the BMJ meta-analysis, oral semaglutide at optimized doses produced roughly 11% body weight reduction beyond lifestyle modification, placing it in the intermediate effectiveness tier alongside injectable semaglutide’s roughly 10%.¹¹ Newer oral formulations and entirely different oral incretin drugs like orforglipron (a small molecule rather than a peptide) are in development, and could eventually make weekly injections unnecessary for many patients.

Emerging Uses Beyond Obesity

Because GLP-1 receptors are found throughout the body, not just in the gut and brain regions that control appetite, researchers are finding that these drugs may affect conditions that have nothing obvious to do with weight. Among the most intriguing lines of investigation is substance use disorders. Preclinical studies suggest GLP-1 receptor agonists reduce alcohol and drug-seeking behavior, possibly by dampening the dopamine-driven reward pathways that drive addiction.²⁴ Clinical evidence in humans is still limited and less conclusive, but most early studies support the safety and potential usefulness of GLP-1 drugs for people with alcohol or substance use disorders.

Pain management is another area drawing attention. GLP-1 receptor agonists appear to influence inflammation, oxidative stress, and immune cell behavior in ways that could provide pain relief independent of their metabolic effects.²⁵ These applications are early-stage, and no one should take a GLP-1 drug specifically for pain or addiction today outside of a clinical trial. But the breadth of biological activity being uncovered helps explain why so many patients report unexpected improvements in conditions their doctors did not prescribe the drug to treat.